CD8A and neoplasm: Icaritin has been shown to suppress tumor progression by attenuating splenic extramedullary hematopoiesis (EMH), thereby reducing the generation and activation of MDSCs while simultaneously enhancing the cytotoxic activity of CD8+ T cells [111].